

# Shucaï Zhang

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/334229/publications.pdf>

Version: 2024-02-01

49  
papers

1,168  
citations

516710

16  
h-index

414414

32  
g-index

63  
all docs

63  
docs citations

63  
times ranked

1921  
citing authors

#	ARTICLE	IF	CITATIONS
1	Molecular Epidemiology of EGFR Mutations in Asian Patients with Advanced Non-Small-Cell Lung Cancer of Adenocarcinoma Histology “ Mainland China Subset Analysis of the PIONEER study. PLoS ONE, 2015, 10, e0143515.	2.5	143
2	Circulating tumor DNA analysis depicts subclonal architecture and genomic evolution of small cell lung cancer. Nature Communications, 2018, 9, 3114.	12.8	122
3	Efficacy, safety, and biomarker analysis of ensartinib in crizotinib-resistant, ALK-positive non-small-cell lung cancer: a multicentre, phase 2 trial. Lancet Respiratory Medicine, the, 2020, 8, 45-53.	10.7	105
4	Efficacy, safety, and genetic analysis of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small-cell lung cancer: a phase 2b, multicentre, single-arm, open-label study. Lancet Respiratory Medicine, the, 2021, 9, 829-839.	10.7	66
5	Early detection of lung cancer by using an autoantibody panel in Chinese population. Oncolmmunology, 2018, 7, e1384108.	4.6	54
6	Clinical Characteristics and Outcomes of Patients with Primary Lung Adenocarcinoma Harboring ALK Rearrangements Detected by FISH, IHC, and RT-PCR. PLoS ONE, 2014, 9, e101551.	2.5	53
7	A single-arm, multicenter, safety-monitoring, phase IV study of icotinib in treating advanced non-small cell lung cancer (NSCLC). Lung Cancer, 2014, 86, 207-212.	2.0	47
8	Overall survival (OS) results from OPTIMAL (CTONG0802), a phase III trial of erlotinib (E) versus carboplatin plus gemcitabine (GC) as first-line treatment for Chinese patients with <i>EGFR</i> mutation-positive advanced non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2012, 30, 7520-7520.	1.6	40
9	Expression and clinical significance of aminopeptidase N/CD13 in non-small cell lung cancer. Journal of Cancer Research and Therapeutics, 2015, 11, 223.	0.9	37
10	China experts consensus on the diagnosis and treatment of advanced stage primary lung cancer (2016) Tj ETQq0 0,0 rgBT /Overlock 10	1.1	34
11	Mechanisms of resistance to irreversible epidermal growth factor receptor tyrosine kinase inhibitors and therapeutic strategies in non-small cell lung cancer. Oncotarget, 2017, 8, 90557-90578.	1.8	34
12	Clinical outcomes of EGFR kinase domain duplication to targeted therapies in NSCLC. International Journal of Cancer, 2019, 144, 2677-2682.	5.1	34
13	Inhibition of DCLK1 sensitizes resistant lung adenocarcinomas to EGFR-TKI through suppression of Wnt/ $\beta$ -Catenin activity and cancer stemness. Cancer Letters, 2022, 531, 83-97.	7.2	27
14	Clinicopathological characteristics and outcomes of ROS1-rearranged patients with lung adenocarcinoma without EGFR, KRAS mutations and ALK rearrangements. Thoracic Cancer, 2015, 6, 413-420.	1.9	25
15	Decoding the Evolutionary Response to Ensartinib in Patients With ALK-Positive NSCLC by Dynamic Circulating Tumor DNA Sequencing. Journal of Thoracic Oncology, 2021, 16, 827-839.	1.1	24
16	PD-L1 Expression and Its Regulation in Lung Adenocarcinoma with ALK Translocation. Interdisciplinary Sciences, Computational Life Sciences, 2019, 11, 266-272.	3.6	19
17	Loss of EGFR confers acquired resistance to AZD9291 in an EGFR-mutant non-small cell lung cancer cell line with an epithelial “mesenchymal transition phenotype. Journal of Cancer Research and Clinical Oncology, 2018, 144, 1413-1422.	2.5	16
18	Routine-Dose and High-Dose Icotinib in Patients with Advanced Non “Small Cell Lung Cancer Harboring EGFR Exon 21-L858R Mutation: the Randomized, Phase II, INCREASE Trial. Clinical Cancer Research, 2020, 26, 3162-3171.	7.0	16

#	ARTICLE	IF	CITATIONS
19	Crizotinib vs platinum-based chemotherapy as first-line treatment for advanced non-small cell lung cancer with different ROS1 fusion variants. <i>Cancer Medicine</i> , 2020, 9, 3328-3336.	2.8	16
20	Isolation of circulating tumor cells and detection of EGFR mutations in patients with non-small cell lung cancer. <i>Oncology Letters</i> , 2019, 17, 3799-3807.	1.8	15
21	The Efficacy and Safety of Icotinib in Patients with Advanced Non-Small Cell Lung Cancer Previously Treated with Chemotherapy: A Single-Arm, Multi-Center, Prospective Study. <i>PLoS ONE</i> , 2015, 10, e0142500.	2.5	14
22	ALK-rearranged squamous cell carcinoma of the lung. <i>Thoracic Cancer</i> , 2021, 12, 1106-1114.	1.9	12
23	Safety and activity of WX-0593 (Iruplinalkib) in patients with ALK- or ROS1-rearranged advanced non-small cell lung cancer: a phase 1 dose-escalation and dose-expansion trial. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 25.	17.1	12
24	ALK-rearranged squamous cell lung cancer: a case report. <i>International Journal of Clinical and Experimental Pathology</i> , 2015, 8, 2195-8.	0.5	11
25	Infiltration of CD8 FOXP3 T cells, CD8 T cells, and FOXP3 T cells in non-small cell lung cancer microenvironment. <i>International Journal of Clinical and Experimental Pathology</i> , 2020, 13, 880-888.	0.5	11
26	Efficacy and safety of alflutinib (AST2818) in patients with T790M mutation-positive NSCLC: A phase IIb multicenter single-arm study. <i>Journal of Clinical Oncology</i> , 2020, 38, 9602-9602.	1.6	10
27	CD137 ligand feedback upregulates PD-L1 expression on lung cancer via T cell production of IFN- $\gamma$ . <i>Thoracic Cancer</i> , 2019, 10, 2225-2235.	1.9	9
28	Possibility of brigatinib-based therapy, or chemotherapy plus anti-angiogenic treatment after resistance of osimertinib harboring EGFR T790M-cis-797S mutations in lung adenocarcinoma patients. <i>Cancer Medicine</i> , 2021, 10, 8328-8337.	2.8	9
29	HER2 Exon 20 Insertion Mutations in Lung Adenocarcinoma: Case Series and Response to Pyrotinib. <i>Frontiers in Oncology</i> , 2020, 10, 1162.	2.8	8
30	The Combination of CD147 and MMP-9 Serum Levels Is Identified as Novel Chemotherapy Response Markers of Advanced Non-Small-Cell Lung Cancer. <i>Disease Markers</i> , 2020, 2020, 1-10.	1.3	8
31	Circulating CD137 <sup>+</sup> CD8 <sup>+</sup> T cells accumulate along with increased functional regulatory T cells and thoracic tumour burden in lung cancer patients. <i>Scandinavian Journal of Immunology</i> , 2019, 89, e12765.	2.7	7
32	Dynamic cfDNA Analysis by NGS in EGFR T790M-Positive Advanced NSCLC Patients Failed to the First-Generation EGFR-TKIs. <i>Frontiers in Oncology</i> , 2021, 11, 643199.	2.8	7
33	IGFBP7 overexpression promotes acquired resistance to AZD9291 in non-small cell lung cancer. <i>Biochemical and Biophysical Research Communications</i> , 2021, 571, 38-45.	2.1	7
34	CD155 expression impairs anti-PD1 therapy response in non-small cell lung cancer. <i>Clinical and Experimental Immunology</i> , 2022, 208, 220-232.	2.6	6
35	Origin of the T790M mutation and its impact on the clinical outcomes of patients with lung adenocarcinoma receiving EGFR-TKIs. <i>Pathology Research and Practice</i> , 2019, 215, 946-951.	2.3	5
36	Sequential measurements of serum matrix metalloproteinase 9 to monitor chemotherapy responses in patients with advanced non-small-cell lung cancer. <i>OncoTargets and Therapy</i> , 2016, 9, 3299.	2.0	4

#	ARTICLE	IF	CITATIONS
37	Final overall survival and updated biomarker analysis results from the randomized phase III ICOGEN trial.. Journal of Clinical Oncology, 2012, 30, 7559-7559.	1.6	4
38	Establishment of a prospective multicenter cohort for advanced nonâ€small cell lung cancer in China (CAPTRAâ€Lung study). Thoracic Cancer, 2018, 9, 1795-1800.	1.9	3
39	&lt;p&gt;Glycodelin As A Biomarker Of Advanced Lung Adenocarcinoma Brain Metastases In Patients Treated With EGFR Tyrosine Kinase Inhibitors&lt;/p&gt;. Cancer Management and Research, 2019, Volume 11, 9421-9425.	1.9	3
40	Penpulimab in combination with anlotinib as first-line treatment in advanced nonsquamous non-small-cell lung cancer.. Journal of Clinical Oncology, 2021, 39, e21072-e21072.	1.6	3
41	Prevalence and management of pain in lung cancer patients in northern China: A multicenter crossâ€sectional study. Thoracic Cancer, 2022, 13, 1684-1690.	1.9	3
42	Central nervous system efficacy of furmonertinib versus gefitinib in patients with nonâ€small cell lung cancer with epidermal growth factor receptor mutations: Results from FURLONG study.. Journal of Clinical Oncology, 2022, 40, 9101-9101.	1.6	3
43	Establishment of the first international large-scale, genomic screening platform to identify patients with rare oncogene drivers in non-small cell lung cancer (NSCLC) in East Asia.. Journal of Clinical Oncology, 2020, 38, 9605-9605.	1.6	2
44	Nivolumab-induced Thyroid Dysfunctions in Patients with Previously Treated Non-small Cell Lung Cancer. Interdisciplinary Sciences, Computational Life Sciences, 2019, 11, 287-291.	3.6	1
45	A Modified Method to Isolate Circulating Tumor Cells and Identify by a Panel of Gene Mutations in Lung Cancer. Technology in Cancer Research and Treatment, 2021, 20, 153303382199527.	1.9	1
46	Detection of EGFR and KRAS somatic mutations in tumor tissue and peripheral blood by a liquidchip technology for patients with advanced non-small cell lung cancer.. Journal of Clinical Oncology, 2012, 30, e18142-e18142.	1.6	1
47	A phase II trial of ALK/ROS1 tyrosine kinase inhibitor WX-0593 (iruplinalkib) in <i>ALK</i>-positive and crizotinib-resistant advanced nonâ€small cell lung cancer.. Journal of Clinical Oncology, 2022, 40, 9073-9073.	1.6	1
48	Progression pattern and post-progression treatment of furmonertinib (AST2818) in EGFR T790M mutation positive NSCLC patients: A post-hoc analysis from a multicenter, single-arm study.. Journal of Clinical Oncology, 2021, 39, e21071-e21071.	1.6	0
49	An updated analysis of ICOGEN to demonstrate utility of a blood-based proteomic test to predict outcomes in EGFR TKI treated patients.. Journal of Clinical Oncology, 2017, 35, e20655-e20655.	1.6	0